Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma

References

• Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221–236.
   PubMedGoogle Scholar
• Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004;22:2982–2984.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, . ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, . Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM, . Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26: 2258–2263.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Mudie NY, Swerdlow AJ, Higgins CD, . Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006;24:1568–1574.
   PubMed Web of Science ®Google Scholar
• Tward JD, Wendland MM, Shrieve DC, . The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108–115.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, . Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 2008;93:1335–1342.
   PubMed Web of Science ®Google Scholar
• Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43:1507–1529.
   PubMed Web of Science ®Google Scholar
• Press OW. Evidence mounts for the efficacy of radio immuno-therapy for B-cell lymphomas. J Clin Oncol 2008;26:5147–5150.
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90Y)-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786–792.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, . Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009;113:3891–3895.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Weller E, Kim K, . Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–3038.
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Colomo L, Jimenez M, . Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797–2804.
   PubMed Web of Science ®Google Scholar
• Nieder C, Licht T, Andratschke N, . Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treat Rev 2003;29:11–19.
   PubMed Web of Science ®Google Scholar
• Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29–36.
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mounier N, . CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:787–792.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Ho AD, Cavallin-Stahl E, . Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435–444.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, . A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769–773.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Rossi G, Franceschetti S, . Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010;16:3998–4004.
   PubMed Web of Science ®Google Scholar